BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 8614003)

  • 1. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer.
    ; Piedbois P; Buyse M; Kemeny N; Rougier P; Carlson R; Allen-Mersh T; O'Connell M; Chang A; Sondak V; Kemeny M; Levy E
    J Natl Cancer Inst; 1996 Mar; 88(5):252-8. PubMed ID: 8614003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basic research supported developments of chemotherapy in nonresectable isolated colorectal liver metastases to a protocol of hepatic artery infusion using mitoxantrone, 5-FU + folinic acid and mitomycin C.
    Link KH; Kornmann M; Leder G; Pillasch AF; Sunelaitis E; Schatz M; Pressmar J; Beger HG
    Gan To Kagaku Ryoho; 1999 Feb; 26(3):269-81. PubMed ID: 10065089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer.
    Mocellin S; Pasquali S; Nitti D
    Cochrane Database Syst Rev; 2009 Jul; (3):CD007823. PubMed ID: 19588444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma.
    Lorenz M; Müller HH
    J Clin Oncol; 2000 Jan; 18(2):243-54. PubMed ID: 10637236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion.
    Focan C; Levi F; Kreutz F; Focan-Henrard D; Lobelle JP; Adam R; Dallemagne B; Jehaes C; Markiewicz S; Weerts J; Bismuth H; Jasmin C; Misset JL
    Anticancer Drugs; 1999 Apr; 10(4):385-92. PubMed ID: 10378673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional chemotherapy for colorectal hepatic metastases: evidence for improved survival with new drug combinations.
    Sutanto-Ward E; Arisawa Y; Tremiterra S; Sigurdson ER
    Ann Surg Oncol; 1996 Jan; 3(1):36-43. PubMed ID: 8770300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin.
    Patt YZ; Hoque A; Lozano R; Pozdur R; Chase J; Carrasco H; Chuang V; Delpassand ES; Ellis L; Curley S; Roh M; Jones DV
    J Clin Oncol; 1997 Apr; 15(4):1432-8. PubMed ID: 9193336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downstaging by regional chemotherapy of non-resectable isolated colorectal liver metastases.
    Link KH; Pillasch J; Formentini A; Sunelaitis E; Leder G; Safi F; Kornmann M; Beger HG
    Eur J Surg Oncol; 1999 Aug; 25(4):381-8. PubMed ID: 10419708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. Meta-Analysis Group in Cancer.
    Durand-Zaleski I; Roche B; Buyse M; Carlson R; O'Connell MJ; Rougier P; Chang AE; Sondak VK; Kemeny MM; Allen-Mersh TG; Fagniez PL; Le Bourgeois JP; Piedbois P
    J Natl Cancer Inst; 1997 Jun; 89(11):790-5. PubMed ID: 9182977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intra-arterial (5-FU/FA and FUDR) versus systemic chemotherapy (5-FU/FA) of non-resectable colorectal liver metastases].
    Gassel HJ; Müller HH; Mattes P; Stieger R; Schramm H; Lorenz M
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1458-60. PubMed ID: 9931911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complications of hepatic artery infusion: a review of 4580 reported cases.
    Barnett KT; Malafa MP
    Int J Gastrointest Cancer; 2001; 30(3):147-60. PubMed ID: 12540027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial.
    Rougier P; Laplanche A; Huguier M; Hay JM; Ollivier JM; Escat J; Salmon R; Julien M; Roullet Audy JC; Gallot D
    J Clin Oncol; 1992 Jul; 10(7):1112-8. PubMed ID: 1296590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer.
    Kemeny N; Capanu M; D'Angelica M; Jarnagin W; Haviland D; Dematteo R; Fong Y
    Ann Oncol; 2009 Jul; 20(7):1236-41. PubMed ID: 19233901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic arterial chemotherapy in combination with systemic chemotherapy compared with hepatic arterial chemotherapy alone for liver metastases from colorectal cancer: results of a multi-centric randomized study.
    Fiorentini G; Cantore M; Rossi S; Vaira M; Tumolo S; Dentico P; Mambrini A; Bernardeschi P; Turrisi G; Giovanis P; Guadagni S; Valori V; De Simone M
    In Vivo; 2006; 20(6A):707-9. PubMed ID: 17203750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases.
    Samaras P; Breitenstein S; Haile SR; Stenner-Liewen F; Heinrich S; Feilchenfeldt J; Renner C; Knuth A; Pestalozzi BC; Clavien PA
    Ann Surg Oncol; 2011 Jul; 18(7):1924-31. PubMed ID: 21207165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternating hepatic arterial infusion and systemic chemotherapy for liver metastases from colorectal cancer: a phase II trial using intermittent percutaneous hepatic arterial access.
    Copur MS; Capadano M; Lynch J; Goertzen T; McCowan T; Brand R; Tempero M
    J Clin Oncol; 2001 May; 19(9):2404-12. PubMed ID: 11331319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional chemotherapy of nonresectable colorectal liver metastases with mitoxantrone, 5-fluorouracil, folinic acid, and mitomycin C may prolong survival.
    Link KH; Sunelaitis E; Kornmann M; Schatz M; Gansauge F; Leder G; Formentini A; Staib L; Pillasch J; Beger HG
    Cancer; 2001 Dec; 92(11):2746-53. PubMed ID: 11753947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining the role of hepatic arterial infusion chemotherapy in metastatic colorectal cancer.
    Whisenant J; Venook A
    Oncology (Williston Park); 2004 May; 18(6):762-8; discussion 769-73. PubMed ID: 15214595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The role of prophylactic hepatic arterial infusion chemotherapy after potentially curative resection of hepatic metastases from colorectal cancer].
    Tono T; Monden T
    Nihon Geka Gakkai Zasshi; 2000 Aug; 101(8):568-73. PubMed ID: 10976444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52.
    Bolton JS; O'Connell MJ; Mahoney MR; Farr GH; Fitch TR; Maples WJ; Nagorney DM; Rubin J; Fuloria J; Steen PD; Alberts SR
    Clin Colorectal Cancer; 2012 Mar; 11(1):31-7. PubMed ID: 21729678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.